You just read:

AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients

News provided by

AbbVie

Mar 07, 2019, 08:46 ET